☆ 4.3 Article

Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients

MOLECULAR DIAGNOSIS & THERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force

Kiat Hon Tony Lim et al.

Summary: NTRK gene fusions are detected in a wide range of tumor types, presenting an attractive option for using TRK inhibitors as cancer therapy. Clinical studies have shown efficacious outcomes with TRK inhibitors in NTRK fusion-bearing cancers. Testing for NTRK gene fusions in advanced malignancies is important but presents practical and financial challenges.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib

Ahmad Awada et al.

Summary: Fusions of NTRK genes are common in various types of cancers, making it possible to develop tumor-agnostic treatments targeting NTRK fusion products. The first-generation Trk inhibitor, larotrectinib, has been approved in the European Union as a tumor-agnostic treatment for NTRK fusion-positive cancers in adults and children. This study aims to provide comprehensive guidance to oncologists regarding NTRK fusion-driven cancer diagnostics and the optimal use of larotrectinib in real-world clinical settings.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

添加到收藏夹

Article Pathology

Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection

Christina Bormann Chung et al.

Summary: This study evaluates the performance of four RNA-based NGS assays for NTRK fusion detection, showing good specificity but varying quality control pass rates. The comparison informs optimal assay selection for identifying patients with NTRK fusion-positive tumors.

JOURNAL OF MOLECULAR DIAGNOSTICS (2022)

添加到收藏夹

Article Oncology

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

Francois Doz et al.

Summary: In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile.

NEURO-ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib

Erin R. Rudzinski et al.

Summary: NTRK gene fusions are targetable oncogenic drivers independent of tumor type. This study examined the techniques used by local sites to detect tumor NTRK gene fusions in patients enrolled in clinical trials of larotrectinib and reported the characteristics of the detected fusions in different tumor types. The most common local testing approach was RNA-based next-generation sequencing.

CANCER GENETICS (2022)

添加到收藏夹

Review Oncology

NTRK- Rearranged soft tissue neoplasms: A review of evolving diagnostic entities and algorithmic detection methods

Lea F. Surrey et al.

Summary: The spectrum of tumors with NTRK1/2/3 rearrangements has expanded with various partners involved, leading to the proposal of a new diagnostic entity of NTRK-rearranged spindle cell neoplasm for tumors occurring outside of the infant age group. The clinical behavior of NTRK rearranged soft tissue tumors varies, with most showing localized disease and rare metastases. Detection of NTRK rearrangement is crucial for guiding treatment in patients with unresectable and metastatic disease.

CANCER GENETICS (2022)

添加到收藏夹

Correction Oncology

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors (vol 28, pg 1302, 2022)

George D. Demetri et al.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Pathology

NTRK insights: best practices for pathologists

Jaclyn F. Hechtman

Summary: Since the discovery of an oncogenic TRK fusion protein in the early 1980s, our understanding of NTRK fusions and methods to detect them has expanded significantly. The identification of these molecular alterations in cancer patient management has become increasingly important, with the emergence of effective TRK protein inhibitors. Insights into testing methods and implementation within healthcare teams are essential for optimal patient care.

MODERN PATHOLOGY (2022)

添加到收藏夹

Article Oncology

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

Xiuning Le et al.

Summary: This article investigates the efficacy and safety of larotrectinib in patients with TRK fusion-positive salivary gland cancers. The results demonstrate that larotrectinib has robust and durable efficacy in treating different histologies of salivary gland tumors, with minimal side effects. These findings emphasize the importance of testing salivary gland cancer for NTRK gene fusions.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing

Anne Koehne de Gonzalez et al.

Summary: This study examined the detection of NTRK fusions using different methodologies and found that pan-TRK IHC showed limited sensitivity for NTRK3 fusions. False positive samples were observed in tumors with physiologic or non-specific TRK expression. Confirmatory testing using RNA-based NGS was necessary.

CANCER GENETICS (2022)

添加到收藏夹

Article Pathology

Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial

Koen De Winne et al.

Summary: A Belgian ring trial was conducted to harmonise pan-TRK IHC staining protocols and interpretation. Labs using the Ventana ready-to-use system with the EPR17341 clone and recommended protocol settings scored best, but all labs performed well with some small optimization.

VIRCHOWS ARCHIV (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology

Kristoffer S. Rohrberg et al.

Summary: Gene rearrangements involving NTRK genes can result in highly oncogenic fusions, which can be detected and treated with TRK inhibitors. While most patients respond well to TRKi, some may develop resistance and require second-generation inhibitors to overcome it.

DRUGS (2021)

添加到收藏夹

Article Pathology

Comparison of RNA-Based Next-Generation for Sequencing Assays for the Detection of NTRK Gene Fusions

Hyeon J. Park et al.

Summary: The study investigated the performance characteristics of three RNA-based next-generation sequencing methods for detecting NTRK gene fusions and found different sensitivities and specificities among the methods. However, all three methods showed high concordance in clinical sensitivity and equivalent high-level performance in specificity for detecting NTRK fusions in clinical samples.

JOURNAL OF MOLECULAR DIAGNOSTICS (2021)

添加到收藏夹

Article Genetics & Heredity

Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation

Carina Heydt et al.

Summary: Gene fusions are important targets for cancer therapy in lung cancer. RNA-based parallel sequencing methods are potent tools for reliable detection of targetable gene fusions in clinical diagnostics. DNA-based methods also show promise but may result in more false positive results.

BMC MEDICAL GENOMICS (2021)

添加到收藏夹

Article Oncology

Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

P. Garrido et al.

Summary: The recent identification of NTRK gene rearrangements and the development of specific fusion protein inhibitors have revolutionised the diagnostic and clinical management of patients with NTRK-fusion tumours. Three key Spanish medical societies have collaborated to develop a consensus document on the diagnostic, clinical, and therapeutic aspects of these tumours, addressing challenges related to routine detection in the public health care system.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Article Cell Biology

Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry

Lynette M. Sholl et al.

Summary: TRK-targeted therapies are important for patients with NTRK gene fusions in advanced solid tumors, but systematic screening approaches are lacking for these rare fusions in common adult carcinomas. Pan-TRK immunohistochemistry (IHC) has been proposed as a screening method, with reflexive testing strategies being convenient and low-cost. However, the clinical impact of pan-TRK IHC 'piggybacking' on existing reflexive testing strategies in surgical pathology appears negligible, as carcinomas may rarely show high-level pan-TRK expression without an underlying NTRK fusion event.

HISTOPATHOLOGY (2021)

添加到收藏夹

Article Oncology

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Nasser H. Hanna et al.

Summary: The updated guidelines provide evidence-based recommendations for systemic therapy in stage IV NSCLC patients with driver alterations, based on systematic reviews of randomized controlled trials and meeting abstracts. These recommendations emphasize the importance of testing for targetable mutations before initiating therapy, and highlight the use of targeted therapies for specific alterations like ROS-1 fusions and BRAF V600e mutations.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting

Lyudmila Bazhenova et al.

Summary: This study evaluated the characteristics and prognosis of tropomyosin receptor kinase fusion cancer in a real-world setting, finding that patients with tumors containing NTRK gene fusions had a higher risk of death, but co-occurrence with other actionable biomarkers was uncommon.

TARGETED ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion

Daniel J. Shepherd et al.

Summary: This article reports a case of a 26-year-old man with NTRK2-rearranged glioblastoma who showed a temporary response to the NTRK inhibitor larotrectinib. Rebiopsy after disease progression revealed the emergence of a PDGFRA-amplified subclone, highlighting the potential efficacy of targeted therapy and the implications of molecular heterogeneity in glioblastoma.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

C. B. Westphalen et al.

Summary: NTRK gene fusions are rare oncogenic drivers in solid tumors, with a prevalence of 0.30% across various cancers and notable variations based on age, cancer type, and histology. Combining large datasets helps in better understanding the characteristics of these rare molecular subgroups of cancer, revealing unique genomic patterns and fusion partners. The presence of NTRK gene fusions did not correlate with other clinically actionable biomarkers, showing distinct genetic features in NTRK fusion-positive tumors.

NPJ PRECISION ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

D. Gwyn Bebb et al.

Summary: TRK inhibitors larotrectinib and entrectinib have been recently approved in Canada for treating solid tumors with NTRK gene fusions. These gene fusions are found at low frequency in most tumor types, and at higher frequency in rare tumors. The inhibitors have shown impressive efficacy and tolerability in clinical trials. Canada has developed a consensus on testing and treatment for NTRK gene fusions.

CURRENT ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients

Sebastien Perreault et al.

Summary: NTRK gene fusions are oncogenic drivers found at low frequencies in most tumor types, but higher frequencies in rare tumors. Two TRK inhibitors have been approved by Health Canada for the treatment of solid tumors harboring NTRK gene fusions, showing promising results in clinical trials. TRK inhibitor therapy should be considered for children with locally advanced or metastatic TRK fusion cancer when other treatment options have been exhausted.

CURRENT ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer

Derek Wong et al.

PATHOLOGY & ONCOLOGY RESEARCH (2020)

添加到收藏夹

Article Pathology

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

James P. Solomon et al.

MODERN PATHOLOGY (2020)

添加到收藏夹

Article Oncology

Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

Nicole Pfarr et al.

GENES CHROMOSOMES & CANCER (2020)

添加到收藏夹

Article Oncology

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

Ezra Y. Rosen et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

Robert C. Doebele et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour -agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

T. Yoshino et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays

Martina Kirchner et al.

GENES CHROMOSOMES & CANCER (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine

Federica Zito Marino et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Neurosciences

Molecular and clinicopathologic features of gliomas harboring NTRK fusions

Matthew Torre et al.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)

添加到收藏夹

Article Oncology

Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies

Daniel Orbach et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Review Oncology

A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors

Anna Forsythe et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

添加到收藏夹

Article Pathology

Molecular characterization of cancers with NTRK gene fusions

Zoran Gatalica et al.

MODERN PATHOLOGY (2019)

添加到收藏夹

Article Pathology

Testing algorithm for identification of patients with TRK fusion cancer

Frederique Penault-Llorca et al.

JOURNAL OF CLINICAL PATHOLOGY (2019)

添加到收藏夹

Review Pathology

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy

Susan J. Hsiao et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2019)

添加到收藏夹

Article Oncology

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

C. Marchio et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms

James P. Solomon et al.

CANCER RESEARCH (2019)

添加到收藏夹

Article Clinical Neurology

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas

Sherise D. Ferguson et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

A. Drilon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes

Albert J. H. Suurmeijer et al.

GENES CHROMOSOMES & CANCER (2018)

添加到收藏夹

Review Oncology

NTRK fusion-positive cancers and TRK inhibitor therapy

Emiliano Cocco et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma

Alison M. Schram et al.

JCO PRECISION ONCOLOGY (2018)

添加到收藏夹

Article Pathology

Newly described salivary gland tumors

Alena Skalova et al.

MODERN PATHOLOGY (2017)

添加到收藏夹

Article Pathology

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions

Jaclyn F. Hechtman et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)

添加到收藏夹

Review Oncology

TRKing Down an Old Oncogene in a New Era of Targeted Therapy

Aria Vaishnavi et al.

CANCER DISCOVERY (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Anchored multiplex FOR for targeted next-generation sequencing

Zongli Zheng et al.

NATURE MEDICINE (2014)

添加到收藏夹

Article Multidisciplinary Sciences

NTRK1 Fusion in Glioblastoma Multiforme

Jinkuk Kim et al.

PLOS ONE (2014)

添加到收藏夹

Article Multidisciplinary Sciences

The landscape of kinase fusions in cancer

Nicolas Stransky et al.

NATURE COMMUNICATIONS (2014)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data

Nameeta Shah et al.

BMC GENOMICS (2013)

添加到收藏夹

Article Genetics & Heredity

The integrated landscape of driver genomic alterations in glioblastoma

Veronique Frattini et al.

NATURE GENETICS (2013)

添加到收藏夹

Article Genetics & Heredity

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

Jinghui Zhang et al.

NATURE GENETICS (2013)

添加到收藏夹

Review Biology

Neuratrophin-regulated signalling pathways

Louis F. Reichardt

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2006)

添加到收藏夹

Article Biology

Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma

S Wadhwa et al.

JOURNAL OF BIOSCIENCES (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.